A Review of Natural Anticancer Products

Authors

  • Ranwa A. Elrayess Department of Zoology, Suez Canal University, Ismailia, Egypt
  • Heba N. Gad El-Hak Department of Zoology, Suez Canal University, Ismailia, Egypt

Keywords:

Anticancer, Natural product, Plant compounds, Marine flora, Microorganisms, Venom

Abstract

Historically, natural products played a forceful role in human treatment ailments. Nowadays, natural products include a large part of current pharmaceutical agents, mostly in the field of cancer therapy. The main aim of this review is to provide a comprehensive summary of the most known natural product used as anticancer globally, including various other natural products. Many of these natural product appears to act through an anticancer mechanism. Overall, natural product research is a vigorous tool to discover novel biologically active components with unique mechanisms of action. Given the diversity of nature, it is sensible to indicate that chemical leads can be produced that are able to interact with most therapeutic targets. This review creates a solid foundation for further study these natural products with additional research and study.

References

Mangal M, Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: Naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2012; 41: D1124-D1129. doi: 10.1093/nar/gks1047

Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005; 78: 431-441. doi: 10.1016/j.lfs.2005.09.012

Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007; 70: 461-477. doi: 10.1021/np068054v

David B, Wolfender JL, Dias DA. The pharmaceutical industry and natural products: Historical status and new trends. Phytochem-istry Reviews. 2015; 14: 299-315. doi: 10.1007/s1110

Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel. 2009; 12: 189-196.

Goldman A, Kulkarni A, Sengupta S. Methods and compo-sitions relating to the treatment of cancer. Google Patents. Web site. https://patentimages.storage.googleapis.com/ef/ da/6d/3ae68471b194c8/WO2016033472A1.pdf. 2015. Accessed July 14, 2019.

Tan G, Gyllenhaal C, Soejarto D. Biodiversity as a source of anticancer drugs. Curr Drug Targets. 2006; 7: 265-277. doi: 10.2174/138945006776054942

Cragg GM, Katz F, Newman DJ, Rosenthal J. The impact of the United Nations convention on biological diversity on natu-ral products research. Nat Prod Rep. 2012; 29: 1407-1423. doi: 10.1039/c2np20091k

Berdy J. Bioactive microbial metabolites. J Antibiot (Tokyo). 2005; 58: 1-26. doi: 10.1038/ja.2005.1

Krause J, Tobin G. Discovery, development, and regulation of natural products. In: Kulka M, ed. Using Old Solutions to New Problems-Natural Drug Discovery in the 21st Century. London, United Kingdom: IntechOpen; 2013: 3-35. doi: 10.5772/56424

Phifer SS, Lee D, Seo EK, et al. Alvaradoins E-N, antitumor and cytotoxic anthracenone C-glycosides from the leaves of al-varadoa haitiensis. J Nat Prod. 2007; 70: 954-961. doi: 10.1021/ np070005a

Shnyder SD, Cooper PA, Millington NJ, Gill JH, Bibby MC. Sodium pancratistatin 3, 4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model. J Nat Prod. 2007; 71: 321-324. doi: 10.1021/np070477p

Winkel-Shirley B. Flavonoid biosynthesis. A colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol. 2001; 126: 485-493. doi: 10.1104/pp.126.2.485

Li H, Wang Z, Liu Y. Review in the studies on tannins activ-ity of cancer prevention and anticancer. Zhong Yao Cai. 2003; 26: 444-448.

Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23: 363-398.

Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008; 66: 445-454. doi: 10.1111/j.1753-4887.2008.00076.x

Greenwell M, Rahman P. Medicinal plants: Their use in an-ticancer treatment. Int J Pharm Sci Res. 2015; 6: 4103-4112. doi: 10.13040/IJPSR.0975-8232.6(10)

Prakash O, Kumar A, Kumar P, Ajeet A. Anticancer poten-tial of plants and natural products: A review. American Journal of Pharmacological Sciences. 2013; 1: 104-115. doi: 10.12691/ajps-1-6-1 El-Hak HNG, et al

Boopathy NS, Kathiresan K. Anticancer drugs from marine flora: An overview. Journal of oncology. 2010; 2010: 214186. doi: 10.1155/2010/214186

Rothschild LJ, Mancinelli RL. Life in extreme environments. Nature. 2001; 409: 1092-1101. doi: 10.1038/35059215

Sarfaraj HM, Sheeba F, Saba A, Khan M. Marine natural prod-ucts: A lead for Anti-cancer. Indian Journal of Geo-Marine Sciences. 2012; 41(1): 27-39.

Kalimuthu S, Se-Kwon K. Cell survival and apoptosis signal-ing as therapeutic target for cancer: Marine bioactive compounds. Int J Mol Sci.. 2013; 14: 2334-2354. doi: 10.3390/ijms14022334

Haefner B. Drugs from the deep: Marine natural products as drug candidates. Drug Discov Today. 2003; 8: 536-544. doi: 10.1016/S1359-6446(03)02713-2

Jha R, Zi-Rong X. Biomedical compounds from marine or-ganisms. Mar Drugs. 2004; 2: 123-146. doi: 10.3390/md203123

Bull AT, Stach JE. Marine actinobacteria: New opportunities for natural product search and discovery. Trends Microbiol. 2007; 15: 491-499. doi: 10.1016/j.tim.2007.10.004

Soria-Mercado IE, Villarreal-Gómez LJ, Rivas GG, Sánchez NEA. Bioactive compounds from bacteria associated to marine algae. In: Sammour R, ed. Biotechnology-Molecular Studies and Novel Applications for Improved Quality of Human Life Croatia. London, United Kingdom: IntechOpen; 2012: 25-44. doi: 10.5772/27842

James A. Potential of bioactive compounds from marine acti-nomycetes against extended specturem of beta lactamase roduc-ing pathogens and cancer cell lines hct 116 and hep g2 an in vitro study. 2016.

Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M. Progress in the development and acquisition of anticancer agents from marine sources. Anna Oncol. 2003; 14: 1607-1615. doi: 10.1093/annonc/mdg443

Bugni TS, Ireland CM. Marine-derived fungi: A chemically and biologically diverse group of microorganisms. Nat Prod Rep. 2004; 21: 143-163. doi: 10.1039/b301926h

Raghukumar C. Marine fungal biotechnology: An ecological perspective. Fungal diversity. 2008; 13: 19-35.

Thajuddin N, Subramanian G. Cyanobacterial biodiversity and potential applications in biotechnology. Current science. 2005; 89: 47-57.

Varshney A, Singh V. Effects of algal compounds on cancer cell line. J Exp Biol. 2013; 1: 337-352.

Costa M, Garcia M, Costa-Rodrigues J, et al. Exploring bioac-tive properties of marine cyanobacteria isolated from the Portu-guese coast: high potential as a source of anticancer compounds. Mar Drugs. 2013; 12: 98-114. doi: 10.3390/md12010098

Gerwick WH, Proteau PJ, Nagle DG, Hamel E, Blokhin A, Slate DL. Structure of curacin A, a novel antimitotic, antiprolif-erative and brine shrimp toxic natural product from the marine cyanobacterium Lyngbya majuscula. The Journal of organic chemistry. 1994; 59: 1243-1245. doi: 10.1021/jo00085a006

Kumar CS, Ganesan P, Suresh P, Bhaskar N. Seaweeds as a source of nutritionally beneficial compounds-a review. Journal of Food Science and Technology. 2008; 45: 1-13.

Zakaria NA, Ibrahim D, Sulaiman SF, Supardy A. Assessment of antioxidant activity, total phenolic content and in-vitro toxicity of Malaysian red seaweed, Acanthophora spicifera. J Chem Pharm Res. 2011; 3: 182-191.

Lavakumar V, Ahamed K, Ravichandran V. Anticancer and antioxidant effect of Acanthophora spicifera against EAC in-duced carcinoma in mice. Journal of Pharmacy Research. 2012; 5: 1503-1507.

Lee JC, Hou MF, Huang HW, et al. Marine algal natural prod-ucts with anti-oxidative, anti-inflammatory, and anti-cancer prop-erties. Cancer Cell Int. 2013; 13: 55. doi: 10.1186/1475-2867-13-55

Ayyad S-EN, Ezmirly ST, Basaif SA, Alarif WM, Badria AF, Badria FA. Antioxidant, cytotoxic, antitumor, and protective DNA damage metabolites from the red sea brown alga Sargas-sum sp. Pharmacognosy Res. 2011; 3: 160-165. doi: 10.4103/0974- 8490.85000

Zhuang C, Itoh H, Mizuno T, Ito H. Antitumor active fu-coidan from the brown seaweed, umitoranoo (Sargassum thun-bergii). Biosci Biotechnol Biochem. 1995; 59: 563-567. doi: 10.1271/ bbb.59.563

Jiang Z, Okimura T, Yokose T, Yamasaki Y, Yamaguchi K, Oda T. Effects of sulfated fucan, ascophyllan, from the brown Alga Ascophyllum nodosum on various cell lines: A comparative study on ascophyllan and fucoidan. J Biosci Bioeng. 2010; 110: 113- 117. doi: 10.1016/j.jbiosc.2010.01.007

Vijayakumar S, Menakha M. Pharmaceutical applications of cyanobacteria-A review. Journal of Acute Medicine. 2015; 5: 15-23. doi: 10.1016/j.jacme.2015.02.004

Dhorajiya B, Malani M, Dholakiya B. Extraction and preserva-tion protocol of anti-cancer agents from marine world. Chemical Sciences Journal. 2012; 2012: 1-12.

Manilal A, Sujith S, Kiran GS, et al. Biopotentials of seaweeds collected from southwest coast of India. Journal of Marine Science and Technology. 2009; 17: 67-73.

Shibata T, Fujimoto K, Nagayama K, Yamaguchi K, Naka-mura T. Inhibitory activity of brown algal phlorotannins against hyaluronidase. International journal of food science & technology. 2002; 37: 703-709. doi: 10.1046/j.1365-2621.2002.00603.x

Amer ME, Abou-Shoer MI, Abdel-Kader MS, El-Shaibany A, Abdel-Salam NA. Alkaloids and flavone acyl glycosides from Acanthus arboreus. Journal of the Brazilian Chemical Society. 2004; 15: 262-266. doi: 10.1590/S0103-50532004000200016

Uzma F, Mohan CD, Hashem A, et al. Endophytic fungi-alter-native sources of cytotoxic compounds: A review. Front Pharmacol. 2018; 9: 309. doi: 10.3389/fphar.2018.00309

Peakman M, Vergani D. Basic and Clinical Immunology E-Book: with STUDENT CONSULT Access. London, UK: Churchill Liv-ingstone; 2009.

Doll R, Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981; 66: 1192-1308.

Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010; 10: 785-794. doi: 10.1038/nrc2934

Cragg GM, Newman DJ. Antineoplastic agents from natural sources: Achievements and future directions. Expert Opin Investig Drugs. 2000; 9: 2783-2797. doi: 10.1517/13543784.9.12.2783

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottes-man MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219-234. doi: 10.1038/nrd1984

Yang W. Fast Viability Assessment of Clostridium Spores: Survival in Extreme environments. [dissertation]. CA, USA: California Insti-tute of Technology; 2010.

Cheesbrough M. District Laboratory Practice in Tropical Countries. Cambridge, England, UK: Cambridge University Press; 2006.

Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story. J Urol. 2008; 179: 53-56. doi: 10.1016/j.juro.2007.08.122

Ogita S, Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N. OK-432 therapy for lymphangioma in children: Why and how does it work? J Pediatr Surg. 1996; 31: 477-480. doi: 10.1016/ s0022-3468(96)90478-9

Roberts NJ, Zhang L, Janku F, et al. Intratumoral injection of clostridium novyi-NT spores induces antitumor responses. Sci Transl Med. 2014; 6: 249ra111. doi: 10.1126/scitranslmed.3008982

Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer. 2007; 43: 490-496. doi: 10.1016/j.ejca.2006.10.005

Hurst LC, Badalamente MA, Hentz VR, et al. Injectable col-lagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009; 361: 968-979. doi: 10.1056/NEJMoa0810866

Łukasiewicz K, Fol M. Microorganisms in the treatment of cancer: Advantages and limitations. Journal of Immunology Research. 2018; 2018. 1-8. doi: 10.1155/2018/2397808

Zhou P, Chen Z, Li H-L, et al. Toxoplasma gondii infection in humans in China. Parasit Vectors. 2011; 4: 165. doi: 10.1186/1756- 3305-4-165

Karamati SA, Hassanzadazar H, Bahmani M, Rafieian Ko-paei M. Herbal and chemical drugs effective on malaria. Asian Pacific Journal of Tropical Disease. 2014; 4: S599-S601. doi: 10.1016/ S2222-1808(14)60686-1

Roos MA, Gennero L, Denysenko T, et al. Microparticles in physiological and in pathological conditions. Cell Biochem Funct. 2010; 28: 539-548. doi: 10.1002/cbf.1695

Ryan JT, Ross RP, Bolton D, Fitzgerald GF, Stanton C. Bioac-tive peptides from muscle sources: Meat and fish. Nutrients. 2011; 3: 765-791. doi: 10.3390/nu3090765

Möller NP, Scholz-Ahrens KE, Roos N, Schrezenmeir J. Bio-active peptides and proteins from foods: Indication for health effects. Eur J Nutr. 2008; 47: 171-182. doi: 10.1007/s00394-008- 0710-2

Qi F, Li A, Inagaki Y, et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2011; 11: 342-349. doi: 10.1016/j. intimp.2010.12.007

Conlon JM, Demandt A, Nielsen PF, Leprince J, Vaudry H, Woodhams DC. The alyteserins: Two families of antimicrobial peptides from the skin secretions of the midwife toad Alytes ob-stetricans (Alytidae). Peptides. 2009; 30: 1069-1073. doi: 10.1016/j. peptides.2009.03.004

Conlon JM. Structural diversity and species distribution of host-defense peptides in frog skin secretions. Cell Mol Life Sci. 2011; 68: 2303-2315. doi: 10.1007/s00018-011-0720-8

Rozek T, Bowie JH, Wallace JC, Tyler MJ. The antibi-otic and anticancer active aurein peptides from the Aus-tralian bell frogs litoria aurea and litoria raniformis. Part 2. Sequence determination using electrospray mass spec-trometry. Rapid Commun Mass Spectrom. 2000; 14: 2002- 2011. doi: 10.1002/1097-0231(20001115)14:21<2002::AID-RCM128>3.0.CO;2-3

van Zoggel H, Hamma-Kourbali Y, Galanth C, et al. Antitu-mor and angiostatic peptides from frog skin secretions. Amino Acids. 2012; 42: 385-395. doi: 10.1007/s00726-010-0815-9 El-Hak HNG, et al

Abdel-Wahab YHA, Power GJ, Flatt PR, Woodhams DC, Rol-lins-Smith LA, Conlon JM. A peptide of the phylloseptin family from the skin of the frog Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity. Peptides. 2008; 29: 2136-2143. doi: 10.1016/j.peptides.2008.09.006

Theansungnoen T, Maijaroen S, Jangpromma N, et al. Cat-ionic antimicrobial peptides derived from crocodylus siamensis leukocyte extract, revealing anticancer activity and apoptotic in-duction on human cervical cancer cells. Protein J. 2016; 35: 202- 211. doi: 10.1007/s10930-016-9662-1

He S, Mao X, Zhang T, et al. Separation and nanoencapsu-lation of antitumor peptides from Chinese three-striped box turtle (Cuora trifasciata). J Microencapsul. 2016; 33: 344-354. doi: 10.1080/02652048.2016.1194904

Aneiros A, Garateix A. Bioactive peptides from marine sources: Pharmacological properties and isolation procedures. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 803: 41-53. doi: 10.1016/j.jchromb.2003.11.005

Goudet C, Chi CW, Tytgat J. An overview of toxins and genes from the venom of the Asian scorpion Buthus martensi Karsch. Toxicon. 2002; 40: 1239-1258.

Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chloro-toxin (TM-601). Expert Opin Drug Deliv. 2007; 4: 175-186. doi: 10.1517/17425247.4.2.175

King GF, Hardy MC. Spider-venom peptides: Structure, pharmacology, and potential for control of insect pests. Annu Rev Entomol. 2013; 58: 475-496. doi: 10.1146/annurev-en-to-120811-153650

Vorontsova OV, Egorova NS, Arseniev AS, Feofanov AV. Haemolytic and cytotoxic action of latarcin Ltc2a. Biochimie. 2011; 93: 227-241. doi: 10.1016/j.biochi.2010.09.016

Moreno M, Giralt E. Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: Melittin, apamin and mastoparan. Toxins (Basel). 2015; 7: 1126-1150. doi: 10.3390/toxins7041126

Gajski G, Garaj-Vrhovac V. Melittin: A lytic peptide with an-ticancer properties. Environ Toxicol Pharmacol. 2013; 36: 697-705. doi: 10.1016/j.etap.2013.06.009

de Azevedo RA, Figueiredo CR, Ferreira AK, et al. Mastoparan induces apoptosis in B16F10-Nex2 melanoma cells via the intrin-sic mitochondrial pathway and displays antitumor activity in vivo. Peptides. 2015; 68: 113-119. doi: 10.1016/j.peptides.2014.09.024

Vyas VK, Brahmbhatt K, Bhatt H, Parmar U. Therapeutic potential of snake venom in cancer therapy: Current perspectives. Asian Pac J Trop Biomed. 2013; 3: 156-162. doi: 10.1016/S2221- 1691(13)60042-8

Calderon LA, Sobrinho JC, Zaqueo KD, et al. Antitumoral activity of snake venom proteins: New trends in cancer therapy. Biomed Res Int. 2014; 2014: 203639. doi: 10.1155/2014/203639

Rádis-Baptista G, Oguiura N, Hayashi MAF, et al. Nucleotide Submit your article to this journal | https://openventio.org/submit-manuscript/ sequence of crotamine isoform precursors from a single South American rattlesnake (Crotalus durissus terrificus). Toxicon. 1999; 37: 973-984.

Ma R, Mahadevappa R, Kwok HF. Venom-based peptide therapy: Insights into anti-cancer mechanism. Oncotarget. 2017; 8: 100908-100930. doi: 10.18632/oncotarget.21740

Downloads

Published

2025-04-07

How to Cite

Ranwa A. Elrayess, & Heba N. Gad El-Hak. (2025). A Review of Natural Anticancer Products. Cancer Studies and Molecular Medicine , 10(1), 11–22. Retrieved from https://openventio.us/index.php/CSMM/article/view/2308

Issue

Vol. 10 No. 1 (2025): Volume 10 Issue 1 2025

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.